These trends coincide with changes in use of prostate specific antigen (PSA) testing following the USPSTF recommendations against PSA-based screening for prostate cancer for men aged 75 years and older in 2008 (57) and for all men in 2012 (58). This evidence concerns the gene KLK3 and prostate carcinoma.